Exscientia signs collaboration agreement with Bayer AG

LONDON: Frontier IP Group’s portfolio company, Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. Under terms of the agreement, Exscientia will initially work on three projects with targets agreed between both…